Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating

Alkermes plc (NASDAQ:ALKS) is one of the high-margin pharma stocks to buy now. Goldman Sachs has initiated coverage of Alkermes plc (NASDAQ:ALKS) with a Buy rating and a $43 price target, citing confidence in the company’s commercial execution and near-term clinical catalysts. The firm pointed to Alkermes’ established portfolio of neuroscience treatments, including Vivitrol and Aristada, as well-positioned to meet fiscal 2025 guidance, with revenue stability supporting broader investment in its development pipeline.

Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating

A pharmacist handing someone a prescription bottle containing the company’s biopharmaceutical product.

In its coverage note, Goldman highlighted the company’s progress in orexin receptor 2 agonist programs, which target sleep and neuropsychiatric disorders. These candidates, still in earlier stages of development, are expected to serve as a key driver of long-term value. The firm noted that upcoming data updates in this segment could serve as a meaningful stock catalyst and help reshape investor sentiment around Alkermes’ growth potential beyond its legacy assets.

Goldman also praised the company’s operational focus and recent steps to streamline costs and sharpen its R&D priorities. Alkermes’ strategic separation of its oncology assets last year has allowed management to concentrate resources on the neurology and psychiatry markets, where demand remains strong and innovation opportunities are expanding.

With shares trading well below the firm’s target, Goldman believes the current valuation offers an attractive entry point ahead of multiple data readouts and commercial milestones expected over the next 12 months.

While we acknowledge the risk and potential of ALKS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALKS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade

Disclosure: None. This article is originally published at Insider Monkey.